TaiMed Biologics Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 96.58 million compared to TWD 91.13 million a year ago. Net loss was TWD 35.98 million compared to TWD 77.88 million a year ago. Basic loss per share from continuing operations was TWD 0.14 compared to TWD 0.31 a year ago. Diluted loss per share from continuing operations was TWD 0.14 compared to TWD 0.31 a year ago.
For the nine months, sales was TWD 236.54 million compared to TWD 337.58 million a year ago. Net loss was TWD 231.51 million compared to TWD 172.22 million a year ago. Basic loss per share from continuing operations was TWD 0.92 compared to TWD 0.68 a year ago. Diluted loss per share from continuing operations was TWD 0.92 compared to TWD 0.68 a year ago.